Surfactant Protein A (SP-A) is a Prognostic Molecular Biomarker in Acute Respiratory Distress Syndrome
https://doi.org/10.15360/1813-9779-2013-3-5
Abstract
The problem of predicting the development and outcomes of acute respiratory distress syndrome (ARDS) remains to be solved. Objective: to estimate the informative value of the plasma levels of surfactant protein A (SP2A) as a prognostic biomarker for the development and outcome of ARDS in patients with severe pyoseptic complications in critical conditions. Subjects and methods. This investigation was conducted at the Research Institute of General Reanimatology (RIGR), Russian Academy of Medical Sciences, in 2010—2012. It enrolled 80 patients (including 25 analyzed ones) in accordance with the inclusion and exclusion criteria, as well as 30 apparently healthy donors. ARDS and its stages were diagnosed using the RIGR criteria. Plasma SP2A levels were determined by enzyme immunoassay using a Human Surfactant Protein A ELISA, RD191139200R kit (BioVendor, USA). The findings were statistically analyzed using a Statistica 7.0 package.Sensitivity and specificity of SP2A testing were determined by ROC analysis. The difference between groups at pResults. In patients with ARDS plasma SP2A level was higher than in those without ARDS within the whole study independing on a day of testing. There were no significant dif2 ferences between plasma SP2A levels in the patients with Stages 1 and 2 ARDS. On day 1, the plasma SP2A content of 24.5 ng/ml had a sensitivity of 60.0% and a specificity of 85.7% in predicting the development of ARDS on days 4—5 of intensive care unit admission (the area under the curve 0.74; 95% confidence interval, 0.527—0.872; p=0.0031). On study day 1, the SP2A level of 38.8 ng/ml had a sensitivity of 65.0% and a specificity of 80.0% in predicting a fatal outcome in patients with ARDS (the area under curve 0.74; 95% confidence interval, 0.577—0.866; p=0.0026). Conclusion. On a day when a severe pyoseptic complication was diagnosed, the SP2A level of 24.5 ng/ml served as a sensitive and specific prognostic biomarker for the development of ARDS on days 4—5 of an intensive care unit stay. Within the first 24 hours (on the day when ARDS was diagnosed), the plasma SP2A content of 38.8 ng/ml was a sensitive and specific prognostic biomarker for death prediction in ARDS. Key words: acute respiratory distress syndrome, surfactant protein A, biomarker, prediction, outcomes.
About the Authors
V. V. MorozA. M. Golubev
A. N. Kuzovlev
V. M, Pisarev
S. G Polovnikov
A. K Shabanov
M. A. Golubev
References
1. Мороз В.В., Голубев А.М.Общая реаниматология.
2. Мороз В.В, Голубев А.М.Принципы диагностики ранних проявлений острого повреждения легких.Общая реаниматология.2006; 2
3. (4): 5—7.
4. Мороз В.В, Власенко А.В, Голубев А.М, Яковлев В.Н., Алексеев В.Г, Булатов Н.Н., Смелая Т.В.Патогенез и дифференциальная диагностика острого респираторного дистресс-синдрома, обусловленного прямыми и непрямыми этиологическими факторами.Общая реаниматология.2011; 7 (3): 5—1
5. Мороз В.В, Власенко А.В, Голубев А.М, Яковлев ВН., Алексеев В.Г, Булатов Н.Н., Смелая Т.В.Дифференцированное лечение острого респираторного дистресс-синдрома, обусловленного прямыми и непрямыми этиологическими факторами.Общая реаниматология.2011; 7 (4): 5—15.
6. Голубев А.М, Мороз В.В., Сундуков Д.В.Патогенез острого респираторного дистресс-синдрома.Общая реаниматология.2012; 8 (4): 13—22.
7. Кузовлев А.Н., Мороз В.В., Голубев А.М., Половников С.Г., Смелая Т.В.Диагностика острого респираторного дистресс-синдрома при нозо-комиальной пневмонии.Общая реаниматология.2009; 5 (6): 5—12.
8. Марченков Ю.В., Власенко А.В., Мороз В.В., Яковлев В.Н.Эволюция диагностики и лечения острого респираторного дистресс-синдрома на основе новейших медицинских технологий.Общая реаниматология.2012; 8 (4): 22—30.
9. Кузьков В.В., Киров М.Ю.Инвазивный мониторинг гемодинамики в интенсивной терапии и анестезиологии. Архангельск: Правда Севера; 200
10. Flori H.R., Ware L.B., Glidden D., Matthay M.A.Early elevation of plasma soluble intercellular adhesion molecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation.Pediatr. Crit. Care Med.2003; 4 (3): 315-321.
11. Parsons P.E., Eisner M.D., Thompson B.T., Matthay M.A., Ancukiewicz M., Bernard G.R., Wheeler A.P.; NHLBIAcute Respiratory Distress Syndrome Clinical Trials Network.Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury.Crit. Care Med.2005; 33(1): 1-6.
12. Agrawal A., Zhuo H, Brady S., LevittJ., SteingrubJ., SiegelM.D., Soto G., Peterson M.W., Chesnutt M.S., Matthay MA., Liu K.D.Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials.Am. J. Physiol. Lung Cell Mol. Physiol.2012; 303 (8): L634-L639.
13. Ware L.B., Matthay M.A., Parsons P.E., Thompson B.T., Januzzi J.L., Eisner M.D.; The National Heart, Lung and Blood Institute ARDS Clinical Trials Network.Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome.Crit. Care Med.2007; 35 (8): 1821-1828.
14. Suratt B.T., Eisner M.D., Calfee C.S., Allard J.B., Whittaker L.A., Engelken D.T., Petty J.M., Trimarchi T., Gauthier L., Parsons P.E.Plasma granulocyte colony-stimulating factor levels correlate with clinical outcomes in patients with acute lung injury.Crit. Care Med.2009; 37 (4): 1322—1328.
15. Proudfoot A., Hind M., Griffiths M.Biomarkers of acute lung injury: worth their salt?BMC Med.2011; 9: 132—140.
16. ГриппиМ.Патофизиология легких. М.: БИНОМ; 2001.
17. Ware L., Koyama T., Billheimer D., Wu W., Bernard G., Thompson B., Brower R., Standiford T., Martin T., Matthay M.Prognostic and patho-genetic value of combining clinical and biochemical indices in patients with acute lung injury.Chest.2010; 137 (2): 288—296.
18. Galsser J., Mallampalli R.Surfactants and its role in the pathology of pulmonary infection.Microbes Infect.2012; 14 (1): 17—25.
19. Calfee C.S., Ware L.B., Glidden D.V., Eisner M.D., Parsons P.E., Thompson B.T., Matthay MA.Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury.Crit. Care Med.2011; 39 (4): 711—717.
20. Doyle I.R., Bersten A.D., Nicholas T.E.Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure.Am. J. Resp. Crit. Care Med.1997; 156 (4 Pt 1): 1217—1229.
21. Wu T.T., Chen T.L., LoonW.S.,Tai Y.T., Cherng Y.G., Chen R.M.Lipopolysaccharide stimulates syntheses of toll-like receptor 2 and surfactant protein-A in human alveolar epithelial A549 cells through upregulating phosphorylation of MEK1 and ERK1/2 and sequential activation of NF-кВ.Cytokine.2011; 55 (1): 40—47.
22. Gnadt M, Kardziev B, Schmidt M., HoggerP.Surfactant protein A (SP-A) and angiotensin converting enzyme (ACE) as early biomarkers for pulmonary edema formation in ventilated human lung lobes.Lung.2012; 190 (4): 431—440.
23. Eisner M., Parsons P., Matthay M., Ware L., Greene K.Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury.Thorax.2003; 589 (11): 983—988.
24. Greene K, Wright J., Steinberg K., RuzinskiJ., Caldwell E., Wong W., Hull W., WhitsettJ., Akino T., Kuroki Y., Nagae H., Hudson L., Martin T.Serial changes of surfactant-associated proteins in lung and serum before and after onset of ARDS.Am.J. Respir. Crit. Care Med.1999; 160 (6): 1843—1850.
25. Cross L., Matthay M.Biomarkers of acute lung injury: insights into the pathogenesis pf acute lung injury.Crit. Care Clin.2011; 27 (2): 355—377.
26. Wright J.R.Immunoregulatory functions of surfactant proteins.Nat. Rev. Immunol2005; 5 (1): 58—68.
27. Pastva A.M., WrightJ.R., Williams K.L.Immunomodulatory roles of surfactant proteins A and D: implications in lung disease.Proc. Am. Thorac. Soc.2007; 4 (3): 252—257.
28. Lin P.M., Wright J.R.Surfactant protein A binds to IgG and enhances phagocytosis of IgG-opsonized erythrocytes.Am. J. Physiol. Lung Cell Mol. Physiol.2006; 291 (6): L1199—L1206.
29. Goto H., Ledford J.G., Mukherjee S., Noble P. W., Williams K.L., Wright J.R.The role of surfactant protein A in bleomycin-induced acute lung injury.Am.J. Resp. Crit. Care Med.2010; 181 (12): 1336—1344.
30. Mukherjee S., Giamberardino C., ThomasJ., Evans K., Goto H., LedfordJ.G., Hsia B., Pastva A.M., Wright J.R.Surfactant protein A integrates activation signal strength to differentially modulate T cell proliferation.J. Immunol.2012; 188 (3): 957—967.
31. Henning L.N., Azad A.K., Parsa K.V., Crowther J.E., Tridandapani S., Schlesinger L.S.Pulmonary surfactant protein A regulates TLR expression and activity in human macrophages.J. Immunol.2008; 180 (12): 7847—7858.
32. Kovach M.A., Standiford T.J.Toll like receptors in diseases of the lung.Int. Immunopharmacol.2011; 11 (10): 1399—1406.
33. ChengI.W., Ware L.B., Greene K.E., Nuckton TJ., Eisner M.D., Matthay MA.Prognostic value of surfactant protein a and D in patients with acute lung injury.Crit. Care Med.2003; 31 (1): 20—27.
Review
For citations:
Moroz V.V., Golubev A.M., Kuzovlev A.N., Pisarev V.M., Polovnikov S.G., Shabanov A.K., Golubev M.A. Surfactant Protein A (SP-A) is a Prognostic Molecular Biomarker in Acute Respiratory Distress Syndrome . General Reanimatology. 2013;9(3):5. (In Russ.) https://doi.org/10.15360/1813-9779-2013-3-5
Views:
1243
Email this article 